SYSTEMS, METHODS, AND KITS FOR GENERATING AND DELIVERYING ENGINEERED T CELLS AND CD38-TARGETED COMPOUNDS AS A COMBINATION THERAPY

AR135272A1Pending Publication Date: 2026-08-05KITE PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
ARP20250100413
Authority / Receiving Office
AR · AR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-16
Filing Date
2025-02-14
Publication Date
2026-08-05
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.

Claims

This description discloses technologies for combination therapies using engineered T cells and a CD38-targeting compound. These technologies specifically address challenges arising from combining therapies and generating and maximizing synergistic effects while preserving and / or enhancing existing individual effects. The engineered T cells may incorporate a modification in CD38 expression that provides protection against the CD38-targeting compound. The CD38-targeting compound may provide protection to the engineered T cells against NK cell-mediated rejection. Furthermore, the combination therapies may target the same cells in a synergistic manner.The technologies described herein can be incorporated into methods of use, methods of preparation, systems, engineered T cells, CD38-targeted compounds, kits, and other useful modalities.